ARTES, Bio Farma in Vaccine Development Pact

ARTES and Bio Farma have entered a collaboration for the development and manufacture of vaccine candidates. ARTES will apply its specialized cell line and process development and VLP based vaccine technology, Metavax, and Bio Farma will provide manufacturing of vaccines for the domestic Indonesian markets.
 
“We are extremely delighted about the mutually agreed collaboration. Bio Farma is a strong and reliable pharmaceutical partner and the only vaccine and antisera producer for humans in Indonesia. We are more than confident, that we along with Bio Farma will develop vaccines highly relevant for the Indonesian and neighboring markets. We expect that especially developments based on our Metavax technology will contribute to Bio Farma´s vaccine portfolio,” Dr. Michael Piontek, founder and managing director of ARTES Biotechnology.
 
ARTES´ Metavax platform is a VLP technology based on modifications to duck hepatitis B virus. The approach elicits a potent immune response and has the potential to offer broader protection than the currently available VLP approaches.